Syneron Medical Ltd and Candela Corporation, and Lutronic Corp and Lutronic Aesthetics Inc, announce that they have entered into a mutually agreeable comprehensive settlement agreement ending the patent disputes between the companies.
Terms of the settlement agreement were not disclosed.
The mutually agreed-upon settlement, limited to Lutronic, protects Candela’s investment in Profound and its patented long pulse and temperature-controlled technology today and in the future. The settlement, through a sublicense from Syneron-Candela, allows Lutronic to market its product in the short pulse category, protecting Candela’s investment in the development of products in the long pulse category with a thermocouple.
For more information, read the full news release at www.prnewswire.com